Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab plus photodynamic therapy versus ranibizumab alone for neovascular age-related macular degeneration
ISRCTN42639823Phase 3Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Jul 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of verteporfin and ranibizumab in exudative macular degeneration (2 arms), sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoint: Proportion gaining at least 15 ETDRS letters at 12 months. Started Jul 2007; status: completed.
02
Drugs
verteporfinranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ISRCTN42639823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN42639823.